Reports Q2 revenue $1.143M, consensus $840k. “We believe the data recently presented from our WTX-124 and WTX-330 clinical programs displays the meaningful impact we can have on patients through our INDUKINE(TM) approach, and we are well positioned to advance both programs towards key inflection points in the coming quarters,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “We continue to focus on enrollment in these two clinical trials and look forward to providing additional clinical data updates as we look to address the unmet medical needs for cancer patients with late-stage disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes
- Werewolf announces initial trial results evaluating INDUKINE for lymphoma
- Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma